Philippe Giraud

List of Publications by Year
in descending order

35 papers	**1,598** citations	430874 **18** h-index	377865 **34** g-index
38 all docs	**38** docs citations	**38** times ranked	**2130** citing authors

#	ARTICLE	IF	CITATIONS
1	Big Data and machine learning in radiation oncology: State of the art and future prospects. Cancer Letters, 2016, 382, 110-117.	7.2	240
2	Respiratory gating for liver tumors: use in dose escalation. International Journal of Radiation Oncology Biology Physics, 2003, 55, 659-668.	0.8	217
3	Conformal radiotherapy for lung cancer: different delineation of the gross tumor volume (GTV) by radiologists and radiation oncologists. Radiotherapy and Oncology, 2002, 62, 27-36.	0.6	199
4	Conformal radiotherapy (CRT) planning for lung cancer: analysis of intrathoracic organ motion during extreme phases of breathing. International Journal of Radiation Oncology Biology Physics, 2001, 51, 1081-1092.	0.8	148
5	Deep Learning and Radiomics predict complete response after neo-adjuvant chemoradiation for locally advanced rectal cancer. Scientific Reports, 2018, 8, 12611.	3.3	142
6	Respiratory Gating Techniques for Optimization of Lung Cancer Radiotherapy. Journal of Thoracic Oncology, 2011, 6, 2058-2068.	1.1	107
7	Radiomics and Machine Learning for Radiotherapy in Head and Neck Cancers. Frontiers in Oncology, 2019, 9, 174.	2.8	85
8	Respiratory Gating for Radiotherapy: Main Technical Aspects and Clinical Benefits. ISRN Pulmonology, 2013, 2013, 1-13.	0.3	51
9	Comparison of end normal inspiration and expiration for gated intensity modulated radiation therapy (IMRT) of lung cancer. Radiotherapy and Oncology, 2005, 75, 149-156.	0.6	49
10	Contribution of Respiratory Gating Techniques for Optimization of Breast Cancer Radiotherapy. Cancer Investigation, 2012, 30, 323-330.	1.3	36
11	Lung volume assessment for a cross-comparison of two breathing-adapted techniques in radiotherapy. International Journal of Radiation Oncology Biology Physics, 2005, 63, 602-609.	0.8	30
12	Probability of mediastinal involvement in non–small-cell lung cancer: a statistical definition of the clinical target volume for 3-dimensional conformal radiotherapy?. International Journal of Radiation Oncology Biology Physics, 2006, 64, 127-135.	0.8	27
13	Helical tomotherapy for resected malignant pleural mesothelioma: Dosimetric evaluation and toxicity. Radiotherapy and Oncology, 2011, 101, 303-306.	0.6	26
14	Labeling for Big Data in radiation oncology: The Radiation Oncology Structures ontology. PLoS ONE, 2018, 13, e0191263.	2.5	26
15	Mobile Technology and Social Media in the Clinical Practice of Young Radiation Oncologists: Results of a Comprehensive Nationwide Cross-sectional Study. International Journal of Radiation Oncology Biology Physics, 2014, 90, 231-237.	0.8	25
16	Clinical Outcomes of Several IMRT Techniques for Patients With Head and Neck Cancer: A Propensity Score–Weighted Analysis. International Journal of Radiation Oncology Biology Physics, 2017, 99, 929-937.	0.8	23
17	The Role of Radiomics in Lung Cancer: From Screening to Treatment and Follow-Up. Frontiers in Oncology, 2021, 11, 603595.	2.8	23
18	Target Definition in the Thorax and Central Nervous System. Seminars in Radiation Oncology, 2005, 15, 146-156.	2.2	19

#	Article	IF	Citations
19	Is IMAT the ultimate evolution of conformal radiotherapy? Dosimetric comparison of helical tomotherapy and volumetric modulated arc therapy for oropharyngeal cancer in a planning study. Physica Medica, 2014, 30, 280-285.	0.7	19
20	Cost Analysis of Complex Radiation Therapy for Patients With Head and Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 95, 654-662.	0.8	19
21	Interpretable Machine Learning Model for Locoregional Relapse Prediction in Oropharyngeal Cancers. Cancers, 2021, 13, 57.	3.7	13
22	Final results from a Phase II study of pemetrexed and cisplatin with concurrent thoracic radiation after Pem-Cis induction in patients with unresectable locally advanced non-squamous non-small cell lung cancer (NSCLC). Lung Cancer, 2015, 88, 160-166.	2.0	12
23	Two-Year Clinical Experience With Tomotherapy: The French National Cancer Institute Project on Implementing New Technology. Cancer Investigation, 2011, 29, 557-563.	1.3	8
24	Conformal Radiotherapy Planning for Lung Cancer: Analysis of Set-Up Uncertainties. Cancer Investigation, 2007, 25, 38-46.	1.3	7
25	Analyzing multiple learning effects in health care using multilevel modeling: Application to radiotherapy at an early stage of innovation. International Journal of Technology Assessment in Health Care, 2009, 25, 232-239.	0.5	6
26	Integrating Multimodal Radiation Therapy Data into i2b2. Applied Clinical Informatics, 2018, 09, 377-390.	1.7	6
27	RE: The Rise of Radiomics and Implications for Oncologic Management. Journal of the National Cancer Institute, 2018, 110, 1275-1276.	6.3	5
28	Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer. Acta Oncológica, 2021, 60, 794-802.	1.8	4
29	In Reply to Fodor and Di Muzio. International Journal of Radiation Oncology Biology Physics, 2016, 96, 1124-1126.	0.8	2
30	Size and Predictive Factors of Microscopic Tumor Extension in Locally Advanced Non-Small Cell Lung Cancer. Practical Radiation Oncology, 2021, 11, 491-501.	2.1	1
31	Cost and Toxicity Comparisons of Two IMRT Techniques for Prostate Cancer: A Micro-Costing Study and Weighted Propensity Score Analysis Based on a Prospective Study. Frontiers in Oncology, 2021, 11, 781121.	2.8	1
32	Early Experience of Helical Tomotherapy for Hepatobiliary Radiotherapy. Case Reports in Hepatology, 2011, 2011, 1-8.	0.7	0
33	Prostate cancer and androgenic alopecia. Expert Review of Endocrinology and Metabolism, 2012, 7, 169-173.	2.4	0
34	Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroup. ESMO Open, 2017, 2, e000141.	4.5	0
35	Final overall survival (OS) results from a phase II study of pemetrexed (Pem) and cisplatin (Cis) with concurrent thoracic radiation (RT) after Pem-Cis induction in patients with unresectable locally advanced (LA) nonsquamous non-small cell lung cancer (NS-NSCLC).. Journal of Clinical Oncology, 2014, 32, 7539-7539.	1.6	0